HM-21001 is under clinical development by Hanmi Pharmaceuticals and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HM-21001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HM-21001 overview

HM-21001 is under development for the treatment of glioblastoma multiforme. The therapeutic candidate is developed as a gene cell therapy. Stem cell constitute of non human enzyme cytosine deaminase (CD). It is administered through intratumor route.

Hanmi Pharmaceuticals overview

Hanmi Pharmaceuticals, a subsidiary of Hanmi Science Co Ltd, develops prescription drugs and over the counter (OTC) drugs. The company’s prescription drugs include antibiotics, antidiarrheal, drugs for osteoporosis, liver supplements and antiemetics. It provides OTC products such as nutritional supplements, calcium supplement, and vitamins, among others. The products of Hanmi Pharmaceuticals are used in the treatment of cancer, depression, dementia, dermatology, diabetes, inflammation, cardiovascular conditions, epilepsy, hepatitis, osteoarthritis, gastrointestinal diseases, obesity, osteoporosis and others. The company operates manufacturing facilities in Hwaseong, Songpa and Pyeongtaek, South Korea. It supplies its products and APIs in various countries in Europe, Asia-Pacific and the Americas. Hanmi Pharmaceuticals is headquartered in Seoul, South Korea.

For a complete picture of HM-21001’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.